Clinical Trials Logo

Parkinson's Disease clinical trials

View clinical trials related to Parkinson's Disease.

Filter by:

NCT ID: NCT00203008 Completed - Parkinson's Disease Clinical Trials

A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma

Start date: January 2003
Phase: N/A
Study type: Observational

Patients with Parkinson's disease will be seen by a dermatologist who will biopsy any suspicious skin lesions.

NCT ID: NCT00202657 Completed - Parkinson's Disease Clinical Trials

Observational Study of Heart Valve Disease in Patients With Parkinson's Disease Treated With Pergolide

Start date: April 2005
Phase: Phase 4
Study type: Observational

The purpose of this study is to determine whether patients with Parkinson's disease and treated with pergolide have a higher risk of heart valve disease compared to patients with Parkinson's disease not treated with pergolide.

NCT ID: NCT00200447 Completed - Parkinson's Disease Clinical Trials

An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)

Start date: March 2004
Phase: Phase 2
Study type: Interventional

This study conducted to more fully evaluate the way that carbidopa/levodopa and entacapone may work in the brain. This research study uses [123I]-IBZM and dynamic SPECT imaging to determine the amount and the duration of dopamine release from specific regions in the brain after treatment with either the combination of carbidopa/levodopa or the combination of carbidopa/levodopa/entacapone.

NCT ID: NCT00199433 Completed - Parkinson's Disease Clinical Trials

A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients

Start date: May 2005
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) as monotherapy in patients with Parkinson's disease.

NCT ID: NCT00199420 Completed - Parkinson's Disease Clinical Trials

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

Start date: July 2004
Phase: Phase 3
Study type: Interventional

To establish the efficacy of 10, 20 and 40 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.

NCT ID: NCT00199407 Completed - Parkinson's Disease Clinical Trials

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Start date: June 2004
Phase: Phase 3
Study type: Interventional

To establish the efficacy of a 20 mg/day dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.

NCT ID: NCT00199394 Completed - Parkinson's Disease Clinical Trials

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of 40 mg a day of istradefylline (KW-6002) for reducing the percentage of awake time spent in the OFF state in patients with advanced Parkinson's disease treated with levodopa.

NCT ID: NCT00199381 Terminated - Parkinson's Disease Clinical Trials

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

Start date: October 2005
Phase: Phase 3
Study type: Interventional

This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.

NCT ID: NCT00199368 Completed - Parkinson's Disease Clinical Trials

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

Start date: October 2004
Phase: Phase 3
Study type: Interventional

This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.

NCT ID: NCT00199355 Completed - Parkinson's Disease Clinical Trials

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Start date: April 2005
Phase: Phase 2
Study type: Interventional

To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.